Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1654MCG

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS 18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 19	JAN 25	Annual Reload of MEDLINE database
NEWS 20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 24	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

```
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:35:17 ON 07 MAR 2010

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.32       1.32

FILE 'REGISTRY' ENTERED AT 13:38:37 ON 07 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 MAR 2010  HIGHEST RN 1208066-55-0
DICTIONARY FILE UPDATES:   5 MAR 2010  HIGHEST RN 1208066-55-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> egtftsdvssylegqaakefiawlvkgrr/sqsp
L1          14 EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQSP

=> d ibib sqide 1-14

L1   ANSWER 1 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   1025170-10-8  REGISTRY
CN   L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-
     arginyl-  (CA INDEX NAME)
OTHER NAMES:
```

CN 4: PN: WO2008056726 SEQID: 5 claimed protein
FS PROTEIN SEQUENCE
SQL 34

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2008056726 claimed SEQID 5

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRR
       ======== ========== ========== =
HITS AT: 3-31

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
        1 REFERENCES IN FILE CA (1907 TO DATE)
        1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 148:554092 CA
TITLE: Glp-1 derivative and use thereof
INVENTOR(S): Jomori, Takahito; Hayashi, Yuji; Makino, Mitsuhiro
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008056726	A1	20080515	WO 2007-JP71687	20071108
JP 2010043001	A	20100225	JP 2006-304380	20061109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2006-304380 20061109
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN

RN 856221-77-7 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-acetyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-acetyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: WO2005060986 SEQID: 11 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29
NTE modified (modifications unspecified)

type	------ location ------		description
modification	Lys-18	-	acetyl<Ac>
modification	Lys-26	-	acetyl<Ac>

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2005060986 claimed SEQID 11

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR
  ========== ========== =========
HITS AT: 1-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C150 H229 N39 O47
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A









PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080194483	A1	20080814	US 2008-8362	20080110
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080015144	A1	20080117	US 2007-582116	20070626

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2550217	A1	20050707	CA 2004-2550217	20041207
EP 1701731	A1	20060920	EP 2004-813201	20041207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20080015144	A1	20080117	US 2007-582116	20070626
US 20080194483	A1	20080814	US 2008-8362	20080110

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 856221-75-5 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-acetyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 9: PN: WO2005060986 SEQID: 9 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29
NTE modified (modifications unspecified)

type	location		description
modification	Lys-26	-	acetyl<Ac>

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2005060986 claimed SEQID 9

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR

HITS AT: 1-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C148 H227 N39 O46

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PAGE 1-B



PAGE 1-C





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080194483	A1	20080814	US 2008-8362	20080110
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080015144	A1	20080117	US 2007-582116	20070626

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2550217	A1	20050707	CA 2004-2550217	20041207
EP 1701731	A1	20060920	EP 2004-813201	20041207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20080015144	A1	20080117	US 2007-582116	20070626
US 20080194483	A1	20080814	US 2008-8362	20080110

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 856221-72-2 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-acetyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO2005060986 SEQID: 6 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29
NTE modified (modifications unspecified)

type	------ location ------		description
modification	Lys-18	-	acetyl<Ac>

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2005060986 claimed SEQID 6

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR

HITS AT: 1-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C148 H227 N39 O46

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PAGE 1-B



PAGE 1-C





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080194483	A1	20080814	US 2008-8362	20080110
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080015144	A1	20080117	US 2007-582116	20070626

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2550217	A1	20050707	CA 2004-2550217	20041207
EP 1701731	A1	20060920	EP 2004-813201	20041207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20080015144	A1	20080117	US 2007-582116	20070626
US 20080194483	A1	20080814	US 2008-8362	20080110

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 856221-69-7 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 3: PN: WO2005060986 SEQID: 3 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	WO2005060986 claimed SEQID

|3

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR
========== ========== =========
HITS AT: 1-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C146 H225 N39 O45
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease

INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080194483	A1	20080814	US 2008-8362	20080110
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080015144	A1	20080117	US 2007-582116	20070626
PRIORITY APPLN. INFO.:			US 2003-529247P	20031212
			WO 2004-US40852	20041207
			US 2007-582116	20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2550217	A1	20050707	CA 2004-2550217	20041207
EP 1701731	A1	20060920	EP 2004-813201	20041207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
US 20080015144 A1 20080117 US 2007-582116 20070626
US 20080194483 A1 20080814 US 2008-8362 20080110
PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 683285-55-4 REGISTRY
CN L-Homoserine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 34
NTE

type	location		description
uncommon	Hse-34	-	-

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRX
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		
US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		
PRIORITY APPLN. INFO.:			JP 2002-299283	20021011
			WO 2003-JP13020	20031010

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 683285-54-3 REGISTRY
CN L-Arginine, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 32

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR RR
========= ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2502118        A1   20040506       CA 2003-2502118  20031010
    AU 2003272970     A1   20040513       AU 2003-272970   20031010
    AU 2003272970     B2   20090528
    EP 1559724        A1   20050803       EP 2003-754074   20031010
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1703424        A    20051130       CN 2003-80101244 20031010
    CN 100354306      C    20071212
    US 20060194720    A1   20060831       US 2005-530125   20051027
    US 7291594        B2   20071106
PRIORITY APPLN. INFO.:                     JP 2002-299283   20021011
                                           WO 2003-JP13020  20031010
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 8 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   683205-72-3  REGISTRY
CN   L-Arginine, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl- (9CI)  (CA INDEX
     NAME)
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  31

SEQ      1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR R
             ======== ========== ========== =
HITS AT:   3-31
MF   C155 H237 N43 O47
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		

US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		
PRIORITY APPLN. INFO.:			JP 2002-299283	20021011
			WO 2003-JP13020	20031010

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-12-9 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 38

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRRRRRR
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		

EP 1559724 A1 20050803 EP 2003-754074 20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1703424 A 20051130 CN 2003-80101244 20031010
CN 100354306 C 20071212
US 20060194720 A1 20060831 US 2005-530125 20051027
US 7291594 B2 20071106
PRIORITY APPLN. INFO.: JP 2002-299283 20021011
WO 2003-JP13020 20031010
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-11-8 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 36

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRRRR
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		
US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		
PRIORITY APPLN. INFO.:			JP 2002-299283	20021011
			WO 2003-JP13020	20031010

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-10-7 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 35

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRRR
======== ========== ========== =

HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

```
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2502118        A1   20040506       CA 2003-2502118  20031010
    AU 2003272970     A1   20040513       AU 2003-272970   20031010
    AU 2003272970     B2   20090528
    EP 1559724        A1   20050803       EP 2003-754074   20031010
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1703424        A    20051130       CN 2003-80101244 20031010
    CN 100354306      C    20071212
    US 20060194720    A1   20060831       US 2005-530125   20051027
    US 7291594        B2   20071106
PRIORITY APPLN. INFO.:                    JP 2002-299283   20021011
                                          WO 2003-JP13020  20031010
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 12 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   682841-09-4  REGISTRY
CN   L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-
     arginyl- (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE
SQL  34

SEQ      1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRR
             ======== ========== ========== =
HITS AT:   3-31

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE  1

ACCESSION NUMBER:         140:380655  CA
TITLE:                    GLP-1 derivatives and transmucosal absorption
                          preparations thereof
INVENTOR(S):              Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki;
                          Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S):       Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 48 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		
US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		
PRIORITY APPLN. INFO.:			JP 2002-299283	20021011
			WO 2003-JP13020	20031010

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-08-3 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 33

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRR
========= ========== ========== =

HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		
US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		

PRIORITY APPLN. INFO.: JP 2002-299283 20021011
WO 2003-JP13020 20031010
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-07-2 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 32

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RR
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption

preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		
US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		

PRIORITY APPLN. INFO.: JP 2002-299283 20021011
WO 2003-JP13020 20031010
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> egtftsdvssylegqaakefiawlvkgr.r/sqsp
L2 190 EGTFTSDVSSYLEGQAAKEFIAWLVKGR.R/SQSP

=> egtftsdvssylegqaakefiawlvkgrr/sqep
4 EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQEP
116602 SQL=29
L3 4 EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQEP
(EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQEP AND SQL=29)

=> egtftsdvssylegqaakefiawlvkgr.r/sqsp
L4 190 EGTFTSDVSSYLEGQAAKEFIAWLVKGR.R/SQSP

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 223.72 TOTAL SESSION 225.04
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:41:00 ON 07 MAR 2010

FILE COVERS 1907 - 7 Mar 2010 VOL 152 ISS 11
FILE LAST UPDATED: 5 Mar 2010 (20100305/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009


```
=> l2 and (diabetes or hyperglycemia)
            73 L2
        173773 DIABETES
         28634 HYPERGLYCEMIA
            35 HYPERGLYCEMIAS
         28653 HYPERGLYCEMIA
                  (HYPERGLYCEMIA OR HYPERGLYCEMIAS)
L5          28 L2 AND (DIABETES OR HYPERGLYCEMIA)

=> l2 and (diabetes or hyperglycemia or stroke)
            73 L2
        173773 DIABETES
         28634 HYPERGLYCEMIA
            35 HYPERGLYCEMIAS
         28653 HYPERGLYCEMIA
                  (HYPERGLYCEMIA OR HYPERGLYCEMIAS)
         46954 STROKE
          3029 STROKES
         48621 STROKE
                  (STROKE OR STROKES)
L6          28 L2 AND (DIABETES OR HYPERGLYCEMIA OR STROKE)

=> d ibib abs total l6

L6   ANSWER 1 OF 28  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2008:1180202  CAPLUS
DOCUMENT NUMBER:          149:418175
TITLE:                    Stable GLP-1 fusion peptides, their production and use
                          in treating diabetes and other disorders
INVENTOR(S):              Wallrapp, Christine; Thoenes, Eric; Geigle, Peter
PATENT ASSIGNEE(S):       Biocompatibles UK Ltd., UK
SOURCE:                   PCT Int. Appl., 86pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008116648	A2	20081002	WO 2008-EP2414	20080327
WO 2008116648	A3	20081231		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1975176	A1	20081001	EP 2007-6321	20070327
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
EP 2129687	A2	20091209	EP 2008-734805	20080327
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: EP 2007-6321 A 20070327
WO 2008-EP2414 W 20080327

OTHER SOURCE(S): MARPAT 149:418175

AB The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homolog of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2-homolog/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homolog of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2-homolog/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

L6 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1179758 CAPLUS
DOCUMENT NUMBER: 149:418174
TITLE: Stable GLP-1 fusion peptides, their production and use in treating diabetes and other disorders
INVENTOR(S): Wallrapp, Christine; Thoenes, Eric; Geigle, Peter
PATENT ASSIGNEE(S): Biocompatibles Uk Ltd., UK

SOURCE: Eur. Pat. Appl., 83 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1975176	A1	20081001	EP 2007-6321	20070327
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2008116648	A2	20081002	WO 2008-EP2414	20080327
WO 2008116648	A3	20081231		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2129687	A2	20091209	EP 2008-734805	20080327
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: EP 2007-6321 A 20070327
WO 2008-EP2414 W 20080327

AB The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homolog of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2-homolog/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1157789 CAPLUS
DOCUMENT NUMBER: 149:395038
TITLE: Stable GLP-1 fusion peptides conjugated to synthetic or natural polymer(s), their production and use for treating diabetes and other diseases
INVENTOR(S): Wallrapp, Christine; Thoenes, Eric; Geigle, Peter
PATENT ASSIGNEE(S): Biocompatibles UK Ltd., UK
SOURCE: PCT Int. Appl., 122pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008113601	A1	20080925	WO 2008-EP2278	20080320
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1972349	A1	20080924	EP 2007-5831	20070321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
EP 2121032	A1	20091125	EP 2008-734709	20080320
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: EP 2007-5831 A 20070321
WO 2008-EP2278 W 20080320

OTHER SOURCE(S): MARPAT 149:395038

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV conjugated to polymers, thereby forming conjugate mols. The fusion peptide of the conjugate mol. comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate mol. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1 (7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g. conjugated to the polymeric component by chemical synthesis. The conjugate mol. may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1151323 CAPLUS
DOCUMENT NUMBER: 149:395037
TITLE: Stable GLP-1 fusion peptides conjugated to synthetic or natural polymer(s), their production and use for treating diabetes and other diseases
INVENTOR(S): Geigle, Peter; Wallrapp, Christine; Thoenes, Eric
PATENT ASSIGNEE(S): Biocompatibles Uk Limited, UK
SOURCE: Eur. Pat. Appl., 120pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1972349	A1	20080924	EP 2007-5831	20070321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2008113601	A1	20080925	WO 2008-EP2278	20080320
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2121032	A1	20091125	EP 2008-734709	20080320
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.:	EP 2007-5831	A	20070321
	WO 2008-EP2278	W	20080320

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV, conjugated to polymers, thereby forming conjugate mols. The fusion peptide of the conjugate mol. comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate mol. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g. conjugated to the polymeric component by chemical synthesis. The conjugate mol. may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER:	2008:981885 CAPLUS
DOCUMENT NUMBER:	149:260057
TITLE:	GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S):	Brownlee, Michael A.
PATENT ASSIGNEE(S):	Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE:	U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116. CODEN: USXXCO
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080194483	A1	20080814	US 2008-8362	20080110
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080015144	A1	20080117	US 2007-582116	20070626

PRIORITY APPLN. INFO.:

US 2003-529247P	P	20031212
WO 2004-US40852	W	20041207
US 2007-582116	A2	20070626

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation in mammalian cells and mammals using the degradation product of glucagon-like peptide 1, GLP-1 (9-36) are provided. Various GLP-1 (9-36) variants are also provided. The cell is selected from the group consisting of a nerve cell, a renal mesangial cell, a pancreatic β cell, an adipocyte, a cardiac myocyte, an endothelial cell or a hepatocyte. In other embodiments, the invention is directed to methods of inhibiting the development of disease due to diabetes, impaired glucose tolerance, stress hyperglycemia , metabolic syndrome, insulin resistance, ischemia/reperfusion injury, endotoxin injury, non alc. steatohepatitis (NASH), alc. liver disease, and/or impaired glucose-stimulated insulin secretion in a mammal, or conditions resulting therefrom. The disease is an atherosclerotic, microvascular, or neurol. disease. More specifically the disease is selected from the group consisting of coronary disease, myocardial infarction, atherosclerotic peripheral vascular disease, cerebrovascular disease, stroke, retinopathy, renal disease, neuropathy, and cardiomyopathy.

L6 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:874968 CAPLUS
DOCUMENT NUMBER: 149:239352
TITLE: Fusion protein of human glucagon-like peptide-1 and application thereof
INVENTOR(S): Luo, Xiaoxing; Hui, Hongxiang; Ma, Xue
PATENT ASSIGNEE(S): Fourth Military Medical University, Pla, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 21pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101220088	A	20080716	CN 2007-10018734	20070924

PRIORITY APPLN. INFO.:

CN 2007-10018734	20070924

OTHER SOURCE(S): MARPAT 149:239352

AB The title fusion protein consists of n segments of peptide A (GLP-1(7-37) [SEQID No.1]) and n segments of peptide B (GLP-2(1-33) [SEQID No.2]). The inventive fusion protein is a prodrug that releases human glucagon-like peptide-1 (GLP-1) after enzymic degradation and thereby has pharmacol. action, and has high bioactivity and long half-time in vivo. The fusion protein can be used to treat or prevent disease or dysfunction associated with GLP-1, especially non-insulin-dependent diabetes mellitus. The invention has the advantages of low cost, simple operation, readily available raw material, and possible commercialized production

L6 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:586638 CAPLUS

DOCUMENT NUMBER: 148:554092

TITLE: Glp-1 derivative and use thereof

INVENTOR(S): Jomori, Takahito; Hayashi, Yuji; Makino, Mitsuhiro

PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008056726	A1	20080515	WO 2007-JP71687	20071108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2010043001	A	20100225	JP 2006-304380	20061109

PRIORITY APPLN. INFO.: JP 2006-304380 A 20061109

AB [PROBLEMS] To provide a novel GLP-1 derivative having a largely improved capability of being absorbed through a mucous membrane. [MEANS FOR SOLVING PROBLEMS] Disclosed is a peptide which has (Lys)n-Arg [wherein n represents an integer of 4 to 8, and Arg is in the form of a carboxylic acid] added to the C-terminus of a peptide comprising an amino acid sequence corresponding to GLP-1 (7-35) or GLP-1 (7-36) or an amino acid sequence having the deletion, substitution and/or addition of one or several amino acid residues in the aforementioned amino acid sequence, having at least 85% homol. to the aforementioned amino acid sequence and having a GLP-1 activity. The amino acid residue at position-8 in the amino acid sequence for GLP-1 is preferably serine or glycine, and the integer "n" is preferably 5.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1303151 CAPLUS

DOCUMENT NUMBER: 147:548045

TITLE: Spherical microcapsules comprising human mesenchymal stem cells expressing and secreting GLP-1 peptides and uses in treating diabetes

INVENTOR(S): Geigle, Peter; Wallrapp, Christine; Thoenes, Eric; Thuermer, Frank
PATENT ASSIGNEE(S): Biocompatibles UK Ltd., UK
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007128443	A2	20071115	WO 2007-EP3775	20070427
WO 2007128443	A3	20080522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1854455	A1	20071114	EP 2006-9678	20060510
EP 1854455	B1	20091007		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
AT 444741	T	20091015	AT 2006-9678	20060510
AU 2007247511	A1	20071115	AU 2007-247511	20070427
CA 2649902	A1	20071115	CA 2007-2649902	20070427
EP 2015736	A2	20090121	EP 2007-724702	20070427
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009536166	T	20091008	JP 2009-508185	20070427
IN 2008DN09530	A	20090619	IN 2008-DN9530	20081114
CN 101489539	A	20090722	CN 2007-80026009	20090109

PRIORITY APPLN. INFO.: EP 2006-9678 A 20060510
WO 2007-EP3775 W 20070427

OTHER SOURCE(S): MARPAT 147:548045

AB The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present application is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapsules e.g. in the treatment of type 2 diabetes, weight disorders, neurodegenerative disorders or for the treatment of disorders and diseases or conditions associated to apoptosis. The cells contained in the core of the spherical microcapsule are selected from human mesenchymal stem cells, differentiated cells derived from human mesenchymal stem cells, including osteoblasts, chondrocytes, fat cells (adipocytes), or neuron-like cells including brain cells.

L6 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:355992 CAPLUS

DOCUMENT NUMBER: 146:351951
TITLE: Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
INVENTOR(S): Geigle, Peter; Wallrapp, Christine; Thoenes, Eric
PATENT ASSIGNEE(S): Biocompatibles UK Limited, UK
SOURCE: Eur. Pat. Appl., 55pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1767545	A1	20070328	EP 2005-20718	20050922
EP 1767545	B1	20091111		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
EP 2045265	A1	20090408	EP 2008-21837	20050922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
AT 448247	T	20091115	AT 2005-20718	20050922
AU 2006299134	A1	20070412	AU 2006-299134	20060922
CA 2619053	A1	20070412	CA 2006-2619053	20060922
WO 2007039140	A1	20070412	WO 2006-EP9226	20060922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1926748	A1	20080604	EP 2006-792228	20060922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009508505	T	20090305	JP 2008-531616	20060922
ZA 2008003488	A	20091028	ZA 2008-3488	20060922
IN 2008DN00642	A	20080711	IN 2008-DN642	20080123
MX 2008003591	A	20080410	MX 2008-3591	20080313
CN 101273058	A	20080924	CN 2006-80035036	20080324
KR 2008064840	A	20080709	KR 2008-709543	20080421

PRIORITY APPLN. INFO.: EP 2005-20718 A3 20050922
WO 2006-EP9226 W 20060922

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:736536 CAPLUS
DOCUMENT NUMBER: 145:159868
TITLE: Stem cell and/or progenitor cells transplantation and methods for treating diabetes
INVENTOR(S): Harman, Mitchell
PATENT ASSIGNEE(S): Kronos Longevity Research Institute, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006079107	A2	20060727	WO 2006-US2626	20060123
WO 2006079107	A3	20070913		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-646476P P 20050122
AB The present invention relates to treatments for diabetes, particularly type 1 diabetes of human. The invention relates to methods and compns. for administering donor cells (e.g., stem cells and/or progenitor cells) to a type 1 diabetic subject and differentiating the stem cells in vivo to produce insulin secreting cells. Certain aspects of the invention relate to kits including one or more donor cells and/or pancreatic differentiation factors and/or immunosuppressant agents.

L6 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:209376 CAPLUS
DOCUMENT NUMBER: 144:247750
TITLE: Induction of hormone gene expression and insulin secretion in pancreatic β cells by islet cell autoantigen ICA512
INVENTOR(S): Trajkovski, Mirko; Mziaut, Hassan; Solimena, Michele
PATENT ASSIGNEE(S): Technische Universitaet Dresden Medizinische Fakultaet Carl Gustav Carus, Germany
SOURCE: Eur. Pat. Appl., 63 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 1632245 A1 20060308 EP 2004-20912 20040902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
CA 2578940 A1 20060323 CA 2005-2578940 20050902
WO 2006029728 A1 20060323 WO 2005-EP9473 20050902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1784207 A1 20070516 EP 2005-791045 20050902
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
JP 2008511297 T 20080417 JP 2007-528787 20050902
US 20090131309 A1 20090521 US 2008-574568 20080201
PRIORITY APPLN. INFO.: EP 2004-20912 A 20040902
WO 2005-EP9473 W 20050902
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Islet cell autoantigen ICA512 and C-terminal fragments derived from it are found to be capable of inducing insulin secretion and peptide hormone biosynthesis in islet cells or neurons. The protein may be cleaved with μ calpain to generate a C-terminal fragment of that is targeted to the nucleus. It is preferred in accordance with the invention that said endocrine cells are β-cells and that said peptide hormone is insulin.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1311452 CAPLUS
DOCUMENT NUMBER: 144:45723
TITLE: Splice variants of members of the pancreatic peptide family for use in therapeutic regulation of metabolism
INVENTOR(S): Shemesh, Ronen; Kliger, Yossef; Neville, Lewis F.; Bernstein, Jeanne; Eshel, Dani
PATENT ASSIGNEE(S): Compugen Ltd., Israel
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118786	A2	20051215	WO 2005-IL588	20050602
WO 2005118786	A3	20080117		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

US 20060052301	A1	20060309	US 2005-145463		20050602
PRIORITY APPLN. INFO.:			US 2004-576414P	P	20040603
			US 2005-672987P	P	20050420

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Splice variants of amylin and other members of the pancreatic polypeptide family, namely peptide YY, peptide Y, and neuropeptide Y, are identified. These variants of these proteins may be useful useful in the treatment of metabolic disorders (no data.). Levels of these proteins may be increased by direct administration, or by delivery of a suitable expression vector carrying the corresponding coding sequence. Alternatively, levels may be lowered by administration of an inhibitor such as an antibody. Administration of a peptide YY variant was effective in slowing weight gain in genetically obese mice.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:961959 CAPLUS
DOCUMENT NUMBER: 143:261378
TITLE: A method for the recombinant production of proteins useful in treatment of obesity and diabetes from the milk of transgenic animals, and therapeutic applications
INVENTOR(S): Olsen, Byron
PATENT ASSIGNEE(S): Gtc Biotherapeutics, Inc., USA; Olsen, Byron
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079525	A2	20050901	WO 2005-US5406	20050218
WO 2005079525	A3	20061228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, SM, US
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20060182744	A1	20060817	US 2005-58458		20050215
PRIORITY APPLN. INFO.:			US 2004-545790P	P	20040219
			US 2005-58458	A1	20050215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The current invention provides a method for the production of therapeutic proteins useful in the treatment of obesity and related conditions through the use of transgenic animals, particularly, from the milk or other bodily fluid of the transgenic animals. In particular the current invention provides for the production of Leptin and other anti-aging mols. in the milk

of transgenic mammals, particularly non-human placental mammals and provides for-the use of such transgenic proteins in therapeutic applications or disease conditions. A nuclear transfer procedure can be conducted to generate a mass of transgenic cells useful for research, serial cloning, or other in vitro use. Another aspect of this invention is directed to a method for treating Type II diabetes mellitus comprising administering to a mammal a therapeutically effective amount of a transgenic protein of interest, a prodrug thereof, or a pharmaceutically acceptable salt thereof in addition to a modified lower dosing of insulin via pump means.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:904226 CAPLUS
DOCUMENT NUMBER: 143:243023
TITLE: Vector constructs comprising mammary tissue-specific promoter for production of transgenic proteins useful in the treatment of obesity and diabetes
INVENTOR(S): Olsen, Byron V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050186608	A1	20050825	US 2005-60291	20050217
PRIORITY APPLN. INFO.:			US 2004-545790P P	20040219

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Transgenic proteins therapeutically useful in the treatment of obesity and related conditions can be produced in and purified from the milk of transgenic animals. Transgene DNA constructs are described which are operatively linked to a mammary tissue-specific promoter (e.g., the β-casein promoter) which enable the transgenic protein product to be expressed in the milk of a transgenic non-human mammal. The peptides are made as transgenic proteins with a suitable transgenic partner such as human recombinant protein of interest.

L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:588685 CAPLUS
DOCUMENT NUMBER: 143:91055
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060986	A1	20050707	WO 2004-US40852	20041207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

CA 2550217	A1	20050707	CA 2004-2550217	20041207
EP 1701731	A1	20060920	EP 2004-813201	20041207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20080015144	A1	20080117	US 2007-582116	20070626
US 20080194483	A1	20080814	US 2008-8362	20080110

PRIORITY APPLN. INFO.:	US 2003-529247P	P	20031212
	WO 2004-US40852	W	20041207
	US 2007-582116	A2	20070626

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation in mammalian cells and mammals using the degradation product of glucagon-like peptide 1, GLP-1 (9-36) are provided. Various GLP-1 (9-36) compns. are also provided.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:485594 CAPLUS

DOCUMENT NUMBER: 143:32219

TITLE: Analogs of glucagon-like peptide-1 for treatment of metabolic, neurological, and aging-associated disorders

INVENTOR(S): Dong, Zheng Xin

PATENT ASSIGNEE(S): Societe de Conseils De Recherches e d'Applications Scientifiques, S.A.S., Fr.

SOURCE: U.S., 174 pp., Cont.-in-part of U.S. Ser. No. 206,601, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6903186	B1	20050607	US 2001-857636	20011102
WO 2000034331	A2	20000615	WO 1999-EP9660	19991207
WO 2000034331	A3	20001116		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1359159	A2	20031105	EP 2003-76490	19991207
EP 1359159	A3	20040721		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
ZA 200304047	A	20040203	ZA 2003-4047	19991207

RU 2288232	C2	20061127	RU 2003-112447	19991207
CN 1935839	A	20070328	CN 2006-10159555	19991207
ZA 2001004478	A	20031201	ZA 2001-4478	20010531
AU 2003202533	A1	20030612	AU 2003-202533	20030327
AU 2003202533	B2	20050421		
US 7268213	B2	20070911	US 2003-629261	20030728
US 20040018981	A1	20040129		
JP 2004131473	A	20040430	JP 2003-283316	20030731
JP 3934092	B2	20070620		
JP 2005132845	A	20050526	JP 2004-363831	20041216
BR 2005000392	A	20060926	BR 2005-392	20050215
US 20050233969	A1	20051020	US 2005-145782	20050606
US 7235628	B2	20070626		
JP 2006151988	A	20060615	JP 2005-374822	20051227
JP 4386887	B2	20091216		
US 20080108566	A1	20080508	US 2007-781096	20070720
JP 2008001710	A	20080110	JP 2007-191581	20070724
US 20090197802	A1	20090806	US 2007-929013	20071030

PRIORITY APPLN. INFO.:	US 1998-111255P	P 19981207
	US 1998-206601	B2 19981207
	WO 1999-EP9660	W 19991207
	AU 2000-19736	A3 19991207
	CN 1999-814187	A3 19991207
	EP 1999-963437	A3 19991207
	JP 2000-586773	A3 19991207
	RU 2001-118855	A 19991207
	US 2001-857636	A2 20011102
	US 2003-629261	A1 20030728
	JP 2003-283316	A3 20030731
	JP 2005-374822	A3 20051227
	US 2007-781096	A1 20070720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:32219

AB Peptide analogs of glucagon-like peptide-1 (GLP-1) with increased plasma half-lives that can be used to treat metabolic, neurol., and disease associated with aging are described. GLP-1 is metabolically unstable, with a plasma half-life of only 1-2 min in vivo, there is therefore a need for GLP-1 analogs that are more active or are more metabolically stable than native GLP-1. Specifically, analogs of human GLP-1(7-36)amide that are agonists for the GLP-1 receptor are described for the treatment of mammalian disorders such as type 1 and type 2 diabetes. The invention provides 773 different analogs, a preferred analog comprising (Ser8,Aib35)hGLP-1(7-36)NH2.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:347172 CAPLUS

DOCUMENT NUMBER: 142:405586

TITLE: Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin

INVENTOR(S): Shemesh, Ronen; Kliger, Yossef; Neville, Lewis F.; Bernstein, Jeanne; Cohen-Dayag, Anat; Eshel, Dani

PATENT ASSIGNEE(S): Compugen Ltd., Israel

SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035761	A1	20050421	WO 2004-IL952	20041017

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-685712 A 20031016
US 2004-576414P P 20040603

AB The present invention relates to alternative splice variants of preproglucagon, glucagon-like peptide-1 (GLP-1) and oxyntomodulin (OXM), vectors and compns. comprising same, and methods of use thereof. This invention provides peptides, nucleic acid sequences which encode same, analogs and derivs. thereof, antibodies, which specifically recognize the variant sequences, compns. comprising same and methods of use thereof. These splice isoforms showed activities in diabetes, nervous system disorders, post surgery treatment, obesity and cardiovascular disease.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:232600 CAPLUS
DOCUMENT NUMBER: 142:311675
TITLE: Use of polypyrimidine tract binding protein in insulin secretory granule biogenesis, drug screening, and therapy
INVENTOR(S): Solimena, Michele; Knoch, Klaus-Peter
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Germany; Technische Universitaet Dresden Medizinische Fakultaet Carl Gustav Carus
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023231	A1	20050317	WO 2004-EP10167	20040910

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-20640 A 20030910
EP 2004-3429 A 20040216

AB The present invention relates to a method for stimulating production of secretory granules in peptide hormone-secreting endocrine cells or neurons comprising the step of promoting the presence of polypyrimidine tract binding protein (pPTB) or a biol. active fragment or derivative thereof in the cytoplasm of said cells or neurons. Preferably, the method alternatively or further comprises promoting the activity of pPTB or said biol. active fragment or derivative thereof in the cytoplasm of said cells or neurons. It is also preferred that said promotion comprises the promotion of the nucleocytoplasmic transport of pPTB. In another aspect, the invention relates to a method of screening for an agent capable of stimulating production of secretory granules in peptide hormone-secreting endocrine cells or neurons comprising the steps of (a) contacting a cell capable of forming secretory granules and expressing polypyrimidine tract binding protein (pPTB) or a biol. active fragment or derivative thereof with one or more compds.; and (b) assessing whether said one or more compds. promote the presence or activity of said polypyrimidine tract binding protein (pPTB) or said biol. active fragment or derivative thereof in the cytoplasm of said cell. The invention comprises further methods of screening for an agent useful as a cure for diabetes, sleeping disorders, or depression as well as various medical uses of an agent capable of the promotion/reduction of the presence or activity of polypyrimidine tract binding protein (pPTB) or of a biol. active fragment or derivative thereof. In alternative embodiments, the invention also includes the reduction or down regulation of pPTB or said biol. active fragment or derivative thereof. In examples of the invention, glucose stimulated activation of pPTB, promoted the stability of ICA512, a receptor tyrosine phosphatase-like protein associated with insulin secretory granules, and upregulated ICA512 mRNA. Glucose stimulation promoted the binding of cytosolic pPTB to the 3'-UTR of ICA512 mRNA and pPTB binding activity correlated with ICA512 mRNA stability. Downregulation of pPTB by RNA interference decreased expression of secretory granule components with pPTB-binding sites in the 3'-untranslated region of their mRNAs. PPTB was phosphorylated on serine residue 16 in a cAMP and protein kinase A-dependent process that regulated translocation of pPTB between the nucleus and the cytoplasm.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:732210 CAPLUS
DOCUMENT NUMBER: 141:237101
TITLE: Methods to induce the conversion of intestinal cells into insulin-producing cells with preproglucagon fragments
INVENTOR(S): Taniguchi, Hideki; Suzuki, Atsushi; Eto, Yuzuru
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1454629	A2	20040908	EP 2004-5144	20040304
EP 1454629	A3	20041201		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
WO 2004078195	A1	20040916	WO 2004-JP2001	20040220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 20040214321	A1	20041028	US 2004-793677	20040305
US 7423019	B2	20080909		
PRIORITY APPLN. INFO.:			JP 2003-61836 A	20030307
			JP 2003-358111 A	20031017

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A partial peptide of a preproglucagon peptide comprising at least the amino acid sequence at positions 92-97 of a preproglucagon peptide is used as an effective ingredient of an antidiabetic drug. Methods for the application of this patent to insulin bioindustrial manufacture are also provided.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:718564 CAPLUS
DOCUMENT NUMBER: 141:248703
TITLE: Analogs of glucagon-like peptide-1 for treatment of mammalian disorders
INVENTOR(S): Dong, Zheng Xin
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.C.R.A.S., Fr.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074315	A2	20040902	WO 2004-US4421	20040217
WO 2004074315	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2513307	A1	20040902	CA 2004-2513307	20040217
EP 1594529	A2	20051116	EP 2004-711811	20040217
EP 1594529	B1	20100120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1750842	A	20060322	CN 2004-80004658	20040217
JP 2007524579	T	20070830	JP 2006-503594	20040217
EP 2067483	A1	20090610	EP 2009-156363	20040217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
AT 455555	T	20100215	AT 2004-711811	20040217
TW 283684	B	20070711	TW 2004-93104154	20040219
US 20060217300	A1	20060928	US 2005-546303	20050819

PRIORITY APPLN. INFO.: US 2003-449203P P 20030219
EP 2004-711811 A3 20040217
WO 2004-US4421 W 20040217
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:248703
AB The present invention is directed to peptide analogs of glucagon-like peptide-1 (GLP-1), and more specifically human GLP-1(7-36)amide, and to methods of using such analogs to have agonist effect on the GLP-1 receptor in the treatment of mammalian disorders such as type 1 and type 2 diabetes. Since GLP-1 is metabolically unstable, having a plasma half-life of only 1-2 min in vivo, there is a need for GLP-1 analogs that are more active or are more metabolically stable than native GLP-1. The invention provides 773 different analogs, a preferred analog comprising (Ser8,Aib35)hGLP-1(7-36)NH2.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:648538 CAPLUS
DOCUMENT NUMBER: 141:191072
TITLE: Preparation and use of chemically-modified metabolites of regulatory peptides
INVENTOR(S): Peri, Krishna; Habi, Abdelkrim; Gravel, Denis
PATENT ASSIGNEE(S): Theratechnologies Inc., Can.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067548	A2	20040812	WO 2004-CA131	20040130
WO 2004067548	A3	20041209		
WO 2004067548	B1	20050217		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
US 20050059605	A1	20050317	US 2004-768974	20040130

PRIORITY APPLN. INFO.: US 2003-443860P P 20030131
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:191072
AB The invention relates to peptides B-A-CO-P or their pharmaceutically-acceptable salts, where P is a dipeptidyl-peptidase (DPPIV) peptide metabolite of regulatory peptides obtained by cleavage of the two N-terminal amino acids, A is (hetero)alk(en)(yn)ylene or Ph and B is (un)substituted (hetero)aryl or cycloalkyl. More specifically, the invention relates to conferring biol. activity to metabolites of regulatory peptides by the covalent coupling of small mols. Thus, 3-(4-methoxyphenethylamino)-3-oxopropanoyl-GLP-1 (9-36) was prepared by solid-phase peptide chemical and N-acylation and shown to produce a more significant hypoglycemic response in mice compared to native GLP-1.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:370962 CAPLUS
DOCUMENT NUMBER: 140:380655
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037859	A1	20040506	WO 2003-JP13020	20031010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502118	A1	20040506	CA 2003-2502118	20031010
AU 2003272970	A1	20040513	AU 2003-272970	20031010
AU 2003272970	B2	20090528		
EP 1559724	A1	20050803	EP 2003-754074	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703424	A	20051130	CN 2003-80101244	20031010
CN 100354306	C	20071212		
US 20060194720	A1	20060831	US 2005-530125	20051027
US 7291594	B2	20071106		

PRIORITY APPLN. INFO.:	JP 2002-299283	A	20021011
	WO 2003-JP13020	W	20031010

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Disclosed is a GLP-1 derivative comprising a peptide having an amino acid sequence derived from the amino acid sequence of GLP-1 (7-35) by deletion, substitution and/or addition of one to several amino acids and having a GLP-1 activity to the C-terminus of which a sequence Waa-(Xaa)n-Yaa (wherein Waa represents Arg or Lys; Xaa represents Arg or Lys; n is an integer of from 0 to 14; and Yaa represents Arg, Arg-NH2, Lys, Lys-NH2 or Hse) is added. This derivative has a high transmucosal absorbability. Moreover, tolerance to dipeptidyl peptidase IV can be imparted to the derivative by substituting the 8-position of the GLP-1 amino acid sequence into Ser, while tolerance to trypsin can be imparted thereto by substituting the 26-position into Gln and the 34-position into Asn. The transmucosal absorbability of the above GLP-1 derivative can be further elevated by formulating into a preparation with the
use of a charge-controller fat emulsifier having a surface charge controlled to the neg. level.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:41516 CAPLUS
DOCUMENT NUMBER: 140:105831
TITLE: Pharmaceutical compositions and uses of GLP-1 mimetics for the treatment of diabetes
INVENTOR(S): Steiness, Eva
PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004005342	A1	20040115	WO 2003-DK463		20030702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2490564	A1	20040115	CA 2003-2490564		20030702
AU 2003243929	A1	20040123	AU 2003-243929		20030702
AU 2003243929	B2	20090604			
EP 1525219	A1	20050427	EP 2003-762471		20030702
EP 1525219	B1	20090527			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006515267	T	20060525	JP 2004-518465		20030702
EP 2028192	A1	20090225	EP 2008-16668		20030702
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR					
AT 432289	T	20090615	AT 2003-762471		20030702
ES 2327328	T3	20091028	ES 2003-762471		20030702
MX 2004012497	A	20050714	MX 2004-12497		20041210
US 20060057137	A1	20060316	US 2005-517563		20050708
HK 1075456	A1	20091231	HK 2005-106202		20050722
US 20090088369	A1	20090402	US 2008-277148		20081124
AU 2009202390	A1	20090709	AU 2009-202390		20090615
PRIORITY APPLN. INFO.:			US 2002-393917P	P	20020704
			US 2003-465613P	P	20030424
			AU 2003-243929	A3	20030702
			EP 2003-762471	A3	20030702
			WO 2003-DK463	W	20030702
			US 2005-517563	A1	20050708

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to use of GLP-1 or a related mol. having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a 'drug holiday'. Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related mol. having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD

(3 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:571103 CAPLUS
DOCUMENT NUMBER: 139:122690
TITLE: Albumin fusion proteins for prolonged shelf-life of therapeutic proteins
INVENTOR(S): Ballance, David James; Turner, Andrew John; Rosen, Craig A.; Haseltine, William A.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Delta Biotechnology Limited; Principia Pharmaceutical Corporation
SOURCE: PCT Int. Appl., 598 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003060071	A2	20030724	WO 2002-US40891	20021223
WO 2003060071	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471363	A1	20030724	CA 2002-2471363	20021223
AU 2002364586	A1	20030730	AU 2002-364586	20021223
EP 1463751	A2	20041006	EP 2002-799966	20021223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005514060	T	20050519	JP 2003-560158	20021223
EP 1997829	A1	20081203	EP 2008-75724	20021223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR				
US 20050186664	A1	20050825	US 2004-775204	20040211
US 7141547	B2	20061128		
JP 2006176514	A	20060706	JP 2005-365640	20051219
US 20060194735	A1	20060831	US 2006-429276	20060508
US 7592010	B2	20090922		
US 20060276396	A1	20061207	US 2006-429373	20060508
US 7238667	B2	20070703		
US 20080213886	A1	20080904	US 2006-429374	20060508
US 20080004206	A1	20080103	US 2006-495624	20060731
US 20070244047	A1	20071018	US 2007-714841	20070307
US 20070259815	A1	20071108	US 2007-783419	20070409
US 20080146503	A1	20080619	US 2007-772643	20070702
US 20080153751	A1	20080626	US 2007-929828	20071030
US 20080161243	A1	20080703	US 2007-929714	20071030
US 20080167238	A1	20080710	US 2007-929912	20071030
US 20080167239	A1	20080710	US 2007-929939	20071030
US 20080167240	A1	20080710	US 2007-929953	20071030
US 20090093402	A1	20090409	US 2007-929702	20071030
US 20090099073	A1	20090416	US 2007-929946	20071030

US 20080194481	A1	20080814	US 2007-932823		20071031
JP 2009213477	A	20090924	JP 2009-109615		20090428
PRIORITY APPLN. INFO.:			US 2001-341811P	P	20011221
			US 2002-350358P	P	20020124
			US 2002-351360P	P	20020128
			US 2002-359370P	P	20020226
			US 2002-360000P	P	20020228
			US 2002-367500P	P	20020327
			US 2002-370227P	P	20020408
			US 2002-378950P	P	20020510
			US 2002-382617P	P	20020524
			US 2002-383123P	P	20020528
			US 2002-385708P	P	20020605
			US 2002-394625P	P	20020710
			US 2002-398008P	P	20020724
			US 2002-402131P	P	20020809
			US 2002-402708P	P	20020813
			US 2002-411355P	P	20020918
			US 2002-411426P	P	20020918
			US 2002-414984P	P	20021002
			US 2002-417611P	P	20021011
			US 2002-420246P	P	20021023
			US 2002-423623P	P	20021105
			EP 2002-799966	A3	20021223
			JP 2003-560158	A3	20021223
			WO 2002-US40891	W	20021223
			US 2003-441305P	P	20030122
			US 2003-453201P	P	20030311
			US 2003-467222P	P	20030502
			US 2003-472816P	P	20030523
			US 2003-476267P	P	20030606
			US 2003-505172P	P	20030924
			US 2003-506746P	P	20030930
			WO 2004-US1369	A1	20040120
			US 2004-542274P	P	20040209
			US 2004-775204	A1	20040211
			US 2004-549901P	P	20040305
			US 2004-556906P	P	20040329
			US 2004-636603P	P	20041217
			WO 2005-US4041	A2	20050209
			US 2005-175690	A2	20050707
			US 2005-707521P	P	20050812
			US 2005-712386P	P	20050831
			US 2005-732724P	P	20051103
			US 2006-776914P	P	20060228
			US 2006-781361P	P	20060313
			US 2006-429276	A2	20060508
			US 2006-429373	A3	20060508
			US 2006-810182P	P	20060602
			US 2006-813682P	P	20060615
			US 2006-495624	A2	20060731

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses albumin fusion proteins. Many therapeutic proteins in their native state or when recombinantly produced are typically labile mols. exhibiting short shelf-lives, particularly when formulated in aqueous solns.; fusions of the therapeutic protein with human serum albumin have a longer serum half-life and/or stabilized activity in solution (or in a pharmaceutical composition) in vitro and/or in vivo than the corresponding unfused therapeutic mols. Thus, albumin fusion proteins are provided comprising granulocyte colony-stimulating factor, interleukin 2, parathormone, erythropoietin, interferon β, interferon α2, interferon A/D hybrid, a single-chain insulin analog, growth hormone, and

(7-36)GLP-1. Nucleic acid mols. encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Addnl. the present invention encompasses pharmaceutical compns. comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:571004 CAPLUS
DOCUMENT NUMBER: 139:122689
TITLE: Albumin fusion proteins for prolonged shelf-life of therapeutic proteins
INVENTOR(S): Rosen, Craig A.; Haseltine, William A.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 1086 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003059934	A2	20030724	WO 2002-US40892		20021223
WO 2003059934	A3	20040226			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2484556	A1	20030724	CA 2002-2484556		20021223
AU 2002364587	A1	20030730	AU 2002-364587		20021223
EP 1463752	A2	20041006	EP 2002-799967		20021223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
EP 1997829	A1	20081203	EP 2008-75724		20021223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR					
US 20050054570	A1	20050310	US 2004-775180		20040211
US 7189690	B2	20070313			
JP 2006176514	A	20060706	JP 2005-365640		20051219
US 20060286635	A1	20061221	US 2006-393893		20060331
US 7238660	B2	20070703			
US 20080293629	A1	20081127	US 2007-772591		20070702
JP 2009213477	A	20090924	JP 2009-109615		20090428
PRIORITY APPLN. INFO.:			US 2001-341811P	P	20011221
			US 2002-350358P	P	20020124
			US 2002-359370P	P	20020226
			US 2002-360000P	P	20020228
			US 2002-367500P	P	20020327
			US 2002-370227P	P	20020408
			US 2002-378950P	P	20020510

US 2002-398008P	P	20020724
US 2002-402131P	P	20020809
US 2002-402708P	P	20020813
US 2002-411355P	P	20020918
US 2002-414984P	P	20021002
US 2002-417611P	P	20021011
US 2002-420246P	P	20021023
US 2002-423623P	P	20021105
US 2002-351360P	P	20020128
US 2002-382617P	P	20020524
US 2002-383123P	P	20020528
US 2002-385708P	P	20020605
US 2002-394625P	P	20020710
US 2002-411426P	P	20020918
EP 2002-799966	A3	20021223
JP 2003-560158	A3	20021223
WO 2002-US40892	W	20021223
US 2004-775180	A1	20040211
US 2006-393893	A1	20060331

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses albumin fusion proteins. Many therapeutic proteins in their native state or when recombinantly produced are typically labile mols. exhibiting short shelf-lives, particularly when formulated in aqueous solns.; fusions of the therapeutic protein with human serum albumin have a longer serum half-life and/or stabilized activity in solution (or in a pharmaceutical composition) in vitro and/or in vivo than the corresponding unfused therapeutic mols. Thus, albumin fusion proteins are provided comprising interferon β, interferon α2, insulin, bone morphogenetic protein 9, glucagon-like peptide-I(7-36), a hybrid interferon A/D, and exendin 4. Nucleic acid mols. encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Addnl. the present invention encompasses pharmaceutical compns. comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L6 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:566074 CAPLUS

DOCUMENT NUMBER: 131:194807

TITLE: Insulinotropic N-terminally truncated GLP-1 lipophilic derivatives with protracted action

INVENTOR(S): Knudsen, Liselotte Bjerre; Huusfeldt, Per Olaf

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943705	A1	19990902	WO 1999-DK81	19990225

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,

TR, TT, UA, UG, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9926105	A	19990915	AU 1999-26105		19990225
EP 1056774	A1	20001206	EP 1999-906075		19990225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2002508162	T	20020319	JP 2000-533455		19990225
PRIORITY APPLN. INFO.:			DK 1998-264	A	19980227
			DK 1998-509	A	19980408
			WO 1999-DK81	W	19990225

OTHER SOURCE(S): MARPAT 131:194807

AB The present invention relates to N-terminally truncated derivs. of human glucagon-like peptide-1 (GLP-1) and analogs thereof having a protracted profile of action, as well as the use of such derivs. in pharmaceutical compns. for the treatment of obesity, insulin dependent or non-insulin dependent diabetes mellitus. The GLP-1 derivs. have a lipophilic substituent attached to at least one amino acid residue.

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:580232 CAPLUS
DOCUMENT NUMBER: 121:180232
ORIGINAL REFERENCE NO.: 121:32751a,32754a
TITLE: Preparation of glucagon-like peptide and insulinotropin derivatives for treating type II diabetes.
INVENTOR(S): Andrews, Glenn C.; Daumy, Gaston O.; Francoeur, Michael L.; Larson, Eric R.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325579	A1	19931223	WO 1993-US3388	19930414
W: AU, BR, CA, CZ, DE, JP, KR, NO, NZ, PL, RU, SK, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9340275	A	19940104	AU 1993-40275	19930414
AU 671117	B2	19960815		
EP 646128	A1	19950405	EP 1993-909505	19930414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07504679	T	19950525	JP 1993-501448	19930414
JP 2575298	B2	19970122		
BR 9306551	A	19980915	BR 1993-6551	19930414
PL 176007	B1	19990331	PL 1993-306766	19930414
RU 2128663	C1	19990410	RU 1994-46251	19930414
EP 969016	A2	20000105	EP 1999-110184	19930414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
CA 2138161	C	20031021	CA 1993-2138161	19930414
IL 120890	A	20000831	IL 1993-120890	19930607
HU 64367	A2	19931228	HU 1993-1739	19930614
CN 1085913	A	19940427	CN 1993-108718	19930614
CN 1057098	C	20001004		
NO 9404853	A	19941214	NO 1994-4853	19941214

PRIORITY APPLN. INFO.: US 1992-899073 A1 19920615
EP 1993-909505 A3 19930414
WO 1993-US3388 A 19930414
IL 1993-105928 A3 19930607

OTHER SOURCE(S): MARPAT 121:180232

AB H2NWCO2H (W = His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly, His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg), and derivs. thereof, having pI ≤4 or ≥7, were prepared having insulinotropic activity (no data). Thus, H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-Arg-NH2 was prepared by solid phase synthesis using BOC-protected amino acids on benzhydrylamine resin. The invention also relates to new uses of certain known derivs. of insulinotropin and truncated insulinotropin to enhance insulin action in a mammal by iontophoretic administration of such derivs.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:1520 CAPLUS
DOCUMENT NUMBER: 114:1520
ORIGINAL REFERENCE NO.: 114:327a,330a
TITLE: Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a new world rodent, the degu, Octodon degus
AUTHOR(S): Nishi, Masahiro; Steiner, Donald F.
CORPORATE SOURCE: Howard Hughes Med. Inst., Univ. Chicago, Chicago, IL, 60637, USA
SOURCE: Molecular Endocrinology (1990), 4(8), 1192-8
CODEN: MOENEN; ISSN: 0888-8809
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The degu, Octodon degus, is a South American hystricomorph rodent that is of interest because it develops spontaneous diabetes mellitus and has been found to have islet amyloidosis. To help clarify these problems cDNAs encoding islet amyloid polypeptide (IAPP), insulin, and glucagon precursors were cloned from this species. The predicted amino acid sequence of degu IAPP is very similar to that of nonamyloid-forming guinea pig IAPP. In contrast, degu insulin and the C-terminal region of degu glucagon are highly divergent from those of other mammals, as is also the case in the guinea pig, suggesting the existence of some form of pos. evolutionary pressure on these hormones of carbohydrate metabolism in the hystricomorph rodents.

OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

=> d ibib hitseq 28

L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:1520 CAPLUS
DOCUMENT NUMBER: 114:1520
ORIGINAL REFERENCE NO.: 114:327a,330a
TITLE: Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a new world rodent, the degu, Octodon degus
AUTHOR(S): Nishi, Masahiro; Steiner, Donald F.
CORPORATE SOURCE: Howard Hughes Med. Inst., Univ. Chicago, Chicago, IL,

```
                          60637, USA
SOURCE:                   Molecular Endocrinology (1990), 4(8), 1192-8
                          CODEN: MOENEN; ISSN: 0888-8809
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
IT   130589-22-9     130589-23-0
     RL: PRP (Properties)
        (amino acid sequence of)
RN   130589-22-9  CAPLUS
CN   Glucagon, prepro- (Octodon degus) (9CI)  (CA INDEX NAME)


SEQ      1 MKSIYFVAGL FVMLVQGSWQ HPLQDTEEKP RSFSTSQTDL LDDPDQMNED
        51 KRHSQGTFTS DYSKFLDTRR AQDFLDWLKN TKRNRNEIAK RHDEFERHAE
       101 GTFTSDVSSY LEGQAAKEFI AWLVKGRGRR DFPEEVTIVE ELRRRHADGS
       151 FSDEMNTVLD HLATKDFINW LIQTKITDRK



RN   130589-23-0  CAPLUS
CN   Glucagon, pro- (Octodon degus) (9CI)  (CA INDEX NAME)


SEQ      1 HPLQDTEEKP RSFSTSQTDL LDDPDQMNED KRHSQGTFTS DYSKFLDTRR
        51 AQDFLDWLKN TKRNRNEIAK RHDEFERHAE GTFTSDVSSY LEGQAAKEFI
       101 AWLVKGRGRR DFPEEVTIVE ELRRRHADGS FSDEMNTVLD HLATKDFINW
       151 LIQTKITDRK



OS.CITING REF COUNT:      23    THERE ARE 23 CAPLUS RECORDS THAT CITE THIS
                                RECORD (23 CITINGS)


=> d ibib hitseq 27

L6   ANSWER 27 OF 28  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         1994:580232  CAPLUS
DOCUMENT NUMBER:          121:180232
ORIGINAL REFERENCE NO.:   121:32751a,32754a
TITLE:                    Preparation of glucagon-like peptide and
                          insulinotropin derivatives for treating type II
                          diabetes.
INVENTOR(S):              Andrews, Glenn C.; Daumy, Gaston O.; Francoeur,
                          Michael L.; Larson, Eric R.
PATENT ASSIGNEE(S):       Pfizer Inc., USA
SOURCE:                   PCT Int. Appl., 30 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 9325579            A1    19931223    WO 1993-US3388          19930414
         W:  AU, BR, CA, CZ, DE, JP, KR, NO, NZ, PL, RU, SK, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9340275            A     19940104    AU 1993-40275           19930414
     AU 671117             B2    19960815
     EP 646128             A1    19950405    EP 1993-909505          19930414
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
```

JP 07504679	T	19950525	JP 1993-501448		19930414
JP 2575298	B2	19970122			
BR 9306551	A	19980915	BR 1993-6551		19930414
PL 176007	B1	19990331	PL 1993-306766		19930414
RU 2128663	C1	19990410	RU 1994-46251		19930414
EP 969016	A2	20000105	EP 1999-110184		19930414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE					
CA 2138161	C	20031021	CA 1993-2138161		19930414
IL 120890	A	20000831	IL 1993-120890		19930607
HU 64367	A2	19931228	HU 1993-1739		19930614
CN 1085913	A	19940427	CN 1993-108718		19930614
CN 1057098	C	20001004			
NO 9404853	A	19941214	NO 1994-4853		19941214
PRIORITY APPLN. INFO.:			US 1992-899073	A1	19920615
			EP 1993-909505	A3	19930414
			WO 1993-US3388	A	19930414
			IL 1993-105928	A3	19930607

OTHER SOURCE(S): MARPAT 121:180232

IT 157507-31-8DP, resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for drug for enhancing insulin action)

RN 157507-31-8 CAPLUS

CN Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E



IT 157507-31-8P 157569-66-9DP, succinoylated
157569-66-9P 157629-57-7P 157629-58-8P
157629-61-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for enhancing insulin action)
RN 157507-31-8 CAPLUS
CN Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D





RN 157569-66-9 CAPLUS
CN 7-36-Glucagon-like peptide 1 (Octodon degus), 36a-glycine-36b-L-arginine-(9CI) (CA INDEX NAME)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E



PAGE 2-B



PAGE 2-C



RN 157569-66-9 CAPLUS
CN 7-36-Glucagon-like peptide 1 (Octodon degus), 36a-glycine-36b-L-arginine- (9CI) (CA INDEX NAME)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E



PAGE 2-B





RN 157629-57-7 CAPLUS
CN 7-36-Glucagon-like peptide 1 (Octodon degus), 36a-glycine-36b-L-arginine-36c-L-arginine- (9CI) (CA INDEX NAME)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GRR

RN 157629-58-8 CAPLUS
CN Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-L-arginine-32a-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GRR

RN 157629-61-3 CAPLUS
CN Glucagon-like peptide 1 (Rana catesbeiana), N-(3-carboxy-1-oxopropyl)-3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-20-[N6-(3-carboxy-1-oxopropyl)-L-lysine]-23-L-isoleucine-24-L-alanine-27-L-valine-28-[N6-(3-carboxy-1-oxopropyl)-L-lysine]-31-glycine-32-L-arginine- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> l2 and (diabetes or hyperglycemia or stroke)
73 L2
173773 DIABETES
28634 HYPERGLYCEMIA
35 HYPERGLYCEMIAS
28653 HYPERGLYCEMIA
(HYPERGLYCEMIA OR HYPERGLYCEMIAS)
46954 STROKE
3029 STROKES
48621 STROKE
(STROKE OR STROKES)
L7 28 L2 AND (DIABETES OR HYPERGLYCEMIA OR STROKE)

=>

=> d ibib hitseq 26

L7 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:566074 CAPLUS
DOCUMENT NUMBER: 131:194807
TITLE: Insulinotropic N-terminally truncated GLP-1 lipophilic derivatives with protracted action
INVENTOR(S): Knudsen, Liselotte Bjerre; Huusfeldt, Per Olaf
PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943705	A1	19990902	WO 1999-DK81	19990225
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926105	A	19990915	AU 1999-26105	19990225
EP 1056774	A1	20001206	EP 1999-906075	19990225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002508162	T	20020319	JP 2000-533455	19990225
PRIORITY APPLN. INFO.:			DK 1998-264 A	19980227
			DK 1998-509 A	19980408
			WO 1999-DK81 W	19990225

OTHER SOURCE(S): MARPAT 131:194807
IT 240497-60-3DP, lipophilic derivs. 240497-61-4DP, lipophilic derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of insulinotropic GLP-1 lipophilic derivs. with protracted action)
RN 240497-60-3 CAPLUS
CN L-Arginine, L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginylglycyl- (9CI) (CA INDEX NAME)

SEQ 1 AEGTFTSDVS SYLEGQAAKE FIAWLVKGRG R

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-C

RN 240497-61-4 CAPLUS
CN L-Arginine, L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-

leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SEQ 1 AEGTFTSDVS SYLEGQAAKE FIAWLVKGRG RR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-A



PAGE 2-B



PAGE 2-C







OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	138.54	363.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-23.80	-23.80

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:50:05 ON 07 MAR 2010